Cancer immunomics using autoantibody signatures for biomarker discovery.
The increased incidence of autoantibodies in malignancies has been described since the 1970s. Thus the ability to determine molecular fingerprinting of autoantibodies (antibody signatures) may provide useful clinical diagnostic and prognostic information. This review describes the use of several proteomics approaches for the identification of antigens recognized by these autoantibodies. Serological proteome analysis combines separation of tumor cell proteins on two-dimensional gel electrophoresis gels, Western blotting with sera of patients and healthy subjects, and identification of the detected antigens by MS. Alternatively multiple affinity protein profiling combines isolation of the antigens recognized by patient antibodies by two-dimensional immunoaffinity chromatography and identification by MS/MS. The use and limitations of reverse phase protein microarrays for testing patient serum containing autoantibodies are also considered. Lastly the most important difficulty of any proteomically identified autoantibody signature is validation in patient cohorts or clinical samples.
Caron
Michel
M
Protein Biochemistry and Proteomics Laboratory, UMR CNRS 7033 (BioMoCeTi), Unité de Formation et de Recherche Santé-Médecine-Biologie Humaine, Paris 13 University, 93017 Bobigny cedex, France. caron_prot@yahoo.fr
Choquet-Kastylevsky
Geneviève
G
Joubert-Caron
Raymonde
R
D000912:Antibodies, Neoplasm / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000276:immunology*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods; D006801:Humans; D040901:Proteomics / Q000379:methods*; D053719:Tandem Mass Spectrometry / Q000379:methods
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor